On January 22, 2025, Johnson & Johnson announced its financial results for the fourth quarter and full year of 2024, with total revenue for the year.$88.21 billion (approximately 646.6 billion RMB), a year-on-year increase of 4.3%. Johnson & Johnson's two core business segments - innovative pharmaceuticals andMedical Device, respectively achieved56.964 billionUSD and$31.857 billion in revenue.In the fiscal year 2024, the company achieved sales of $88.21 billion, representing a year-over-year increase of 4.3%. GAAP net income was $1.41 billion, up 5.6% year-over-year, with earnings per share (EPS) reaching $5.79, reflecting an 11.3% year-over-year increase. Adjusted net income was $2.42 billion, down 4.6% year-over-year; adjusted earnings per share were $9.98, up 0.6% year-over-year.
- Innovative Pharmaceutical Business
In the fourth quarter of 2024, the innovative pharmaceuticals business achieved global sales.$14.332 billion, year-on-year growth4.4%。
Among which, the oncology business revenue$5.497 billion, an increase of 19.0% year-on-year, becoming the main growth driver, benefiting from the strong market performance and continuous growth of products such as DARZALEX, ERLEADA, and CARYVYKI.
Immunology Business Revenue$4.238 billion, a decrease of 7.8% year-on-year, mainly due to the loss of market exclusivity for some products and increased competition.Neuroscience, infectious diseases, and cardiovascular/metabolic businesses contributed $1.775 billion, $774 million, and $957 million, respectively.Pulmonary Arterial Hypertension Business Revenue Reached $1.092 Billion, a Year-on-Year Increase of 7.4%, Benefiting from the Market Expansion and Share Growth of OPSUMIT and UPTRAVIGrowth.- Medical Technology Business
In the fourth quarter of 2024, the medical technology business achieved global sales$8.188 billion, a year-on-year increase of 6.7%, with operational growth rates of 7.6% each in the U.S. and international markets.
Cardiovascular Business Revenue$2.062 billion, a year-on-year increase of 23.6%, driven by the strong growth of Electrophysiology and Abiomed products as well as the contribution from the acquisition of Shockwave.Orthopedic ServicesIncome$2.315 billion, an increase of 2.1% year-on-year, driven by the continued growth of knee and trauma-related products.Surgical Business Revenue$2.507 billion, a year-on-year decrease of 0.9%.Vision Business Revenue$1.303 billion, up 7% year on year.9%, benefiting from the market expansion and price optimization strategy of contact lens products.Looking ahead, Johnson & Johnson expects operational sales growth of 2.5%-3.5% in 2025, with adjusted operational earnings per share between $10.75 and $10.95, representing a midpoint growth of 8.7%.
# Executive Evaluation
"Johnson & Johnson achieved strong performance again in 2024, completing several strategically significant investments andAccelerate and strengthen the development of product pipelines in the two major businesses of innovative pharmaceuticals and medical technology.Looking ahead to 2025, we will continue to focus on bringing more revolutionary treatment solutions and innovative breakthroughs to patients, while striving to achieve both short-term and long-term financial goals, creating greater value for our shareholders."
“2024The year was transformative for us. We achieved robust performance growth, accelerated the expansion of our product development pipeline, and consistently maintained a leading position in the industry in terms of innovative R&D investment. As a healthcare company focused on advancing human health through innovative treatment solutions, Johnson & Johnson...In multiple high-need disease areas with unmet demands, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure, continuously contributing to the enhancement of industry standards. With robust financial strength, a differentiated and diversified product portfolio, and an ever-expanding R&D pipeline, we are confident in maintaining rapid growth and leading innovation in the future, accelerating development with significant advantages."
# List of Award-Winning Medical Device Companies
Global Surgical Robotics Industry Awards 2024
Global Medical Technology Innovation Award 2024
Global MedTech Newcomer Award 2024
Global Innovative Medical Device Award 2024
# Overseas Large Medical Device Manufacturers
#EnChina's Major Medical Device ManufacturersMindray Medical｜Lepu Medical|MicroPort｜Weigao Group|United Imaging Healthcare
